Literature DB >> 17578486

Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.

Kristina Löwing1, Eva Aström, Katarina Allbrink Oscarsson, Stefan Söderhäll, Ann-Christin Eliasson.   

Abstract

AIM: To evaluate the effect of intravenous pamidronate therapy on everyday activities, well-being, skeletal pain and bone density in children with osteogenesis imperfecta (OI).
METHODS: In a prospective observational study, monthly intravenous pamidronate infusions were given to 43 children (aged 4 months-16 years) with different severity and form of OI. Outcome measures included the Pediatric Evaluation of Disability Inventory (PEDI), a score of well-being, registration of days with pain and bone density measured by using dual energy X-ray absorptiometry (DXA). Data were collected before and after the first year of treatment.
RESULTS: Self-care and mobility measured by PEDI increased significantly in both the Functional Skill scale and in the Caregiver Assistance scale. The youngest children improved more than the older ones according to the PEDI. The days with skeletal pain were reduced and both well-being and bone density increased.
CONCLUSIONS: Intravenous treatment with bisphosphonates influenced health status, according to the International Classification of Functioning, Disability and Health (ICF). This group of 43 children experienced beneficial effects on everyday activities, skeletal pain, well-being and bone density.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17578486     DOI: 10.1111/j.1651-2227.2007.00390.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  10 in total

1.  Approach to the child with fractures.

Authors:  Alison M Boyce; Rachel I Gafni
Journal:  J Clin Endocrinol Metab       Date:  2011-07       Impact factor: 5.958

2.  Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.

Authors:  G A Otaify; M S Aglan; M M Ibrahim; M Elnashar; R A S El Banna; S A Temtamy
Journal:  Osteoporos Int       Date:  2015-07-03       Impact factor: 4.507

Review 3.  The psychosocial experience of individuals living with osteogenesis imperfecta: a mixed-methods systematic review.

Authors:  Argerie Tsimicalis; Gabrielle Denis-Larocque; Alisha Michalovic; Carolann Lepage; Karl Williams; Tian-Ran Yao; Telma Palomo; Noemi Dahan-Oliel; Sylvie Le May; Frank Rauch
Journal:  Qual Life Res       Date:  2016-02-19       Impact factor: 4.147

4.  Effect of Bisphosphonates on Function and Mobility Among Children With Osteogenesis Imperfecta: A Systematic Review.

Authors:  Christopher S Constantino; Joseph J Krzak; Alissa V Fial; Karen M Kruger; Jacob R Rammer; Katarina Radmanovic; Peter A Smith; Gerald F Harris
Journal:  JBMR Plus       Date:  2019-10-18

5.  Item bank development for a revised pediatric evaluation of disability inventory (PEDI).

Authors:  Helene Dumas; Maria Fragala-Pinkham; Stephen Haley; Wendy Coster; Jessica Kramer; Ying-Chia Kao; Richard Moed
Journal:  Phys Occup Ther Pediatr       Date:  2010-08       Impact factor: 2.360

6.  [Diagnosis and therapy of osteogenesis imperfecta].

Authors:  A Meurer; T Lewens; D Schmitt; T Vetter; P Drees
Journal:  Orthopade       Date:  2008-01       Impact factor: 1.087

7.  Results of a bone splint technique for the treatment of lower limb deformities in children with type I osteogenesis imperfecta.

Authors:  Dasheng Lin; Wenliang Zhai; Kejian Lian; Zhenqi Ding
Journal:  Indian J Orthop       Date:  2013-07       Impact factor: 1.251

Review 8.  Rare bone diseases and their dental, oral, and craniofacial manifestations.

Authors:  B L Foster; M S Ramnitz; R I Gafni; A B Burke; A M Boyce; J S Lee; J T Wright; S O Akintoye; M J Somerman; M T Collins
Journal:  J Dent Res       Date:  2014-04-03       Impact factor: 6.116

9.  Exploring pain interference and self-perceived health status in children with osteogenesis imperfecta - a cross-sectional study.

Authors:  Anna Hallin Provenzano; Eva Åström; Kristina Löwing
Journal:  BMC Musculoskelet Disord       Date:  2022-09-21       Impact factor: 2.562

10.  A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.

Authors:  Alison M Boyce; Marilyn H Kelly; Beth A Brillante; Harvey Kushner; Shlomo Wientroub; Mara Riminucci; Paolo Bianco; Pamela G Robey; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2014-07-17       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.